$0.04 EPS Expected for Ionis Pharmaceuticals, Inc. (IONS) on February, 26

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Corporate Logo

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s earnings release is anticipated by WallStreet on February, 26, according to Faxor. This year’s earnings per share analyst estimate is anticipated to be $0.04. That is 100.00 % up compareed to $0.02 earnings per share for last year. In case of $0.04 earnings per share IONS’s profit could reach $5.50 million. -233.33 % EPS growth is what Wall Street’s predicts after $-0.03 reported EPS last quarter. The stock decreased 0.03% or $0.02 during the last trading session, hitting $58.03.Currently Ionis Pharmaceuticals, Inc. is uptrending after 1.50% change in last February 8, 2018. IONS has also 764,517 shares volume. IONS outperformed the S&P500 by 1.50%.

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics.The firm is valued at $7.98 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and as an adjunct to lipid lowering medications and diet.Last it reported negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug for transthyretin amyloidosis.

For more Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) news announced briefly go to: Seekingalpha.com, Nasdaq.com, Fool.com, Fool.com or Nasdaq.com. The titles are as follows: “Ionis Pharmaceuticals, Inc. (IONS) CEO Stan Crooke on Q2 2018 Results – Earnings Call Transcript – Seeking Alpha” announced on August 07, 2018, “Why Every Investor Should Hold Shares of Biogen Stock – Nasdaq” on July 25, 2018, “Why Ionis Pharmaceuticals Crashed Today – The Motley Fool” with a publish date: April 24, 2018, “3 Top Biotech Stocks to Buy in January – The Motley Fool” and the last “Ionis Pharmaceuticals Reaches Analyst Target Price – Nasdaq” with publication date: November 29, 2018.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.